This document is a USPTO patent application (US20260083766A1) for methods to treat neurodegenerative disorders by reducing nuclear aggregates and modulating adenosine-to-inosine RNA editing. The application, filed on May 16, 2025, by inventors Nandkishore Raghav Belur and Joseph Robert Mazzulli, describes administering adenosine-to-inosine editing modifiers to restore neuronal synaptic function.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on companies. However, it signals potential future developments in pharmaceutical research and development for neurodegenerative diseases. Companies in the pharmaceutical and biotechnology sectors may wish to monitor the progress of this application and related intellectual property.